Vertex Pharmaceuticals Incorporated
Bear Case (25th pct.)
-62.8% vs price
Base Case (Median)
-57.4% vs price
Bull Case (75th pct.)
-32.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $141.72 | -70.4% | High (40%) |
| PE Comparable | $375.36 | -21.6% | Medium (25%) |
| Growth Trajectory DCF | $355.74 | -25.7% | Medium (20%) |
| Graham Number | $166.41 | -65.3% | Medium (40%) |
| EV/EBITDA | $190.21 | -60.3% | Medium (20%) |
| EV/FCF | $290.21 | -39.4% | Medium (20%) |
| Earnings Power Value | $203.88 | -57.4% | Medium (50%) |
Based on 7 out of 8 methods, VRTX appears overvalued at the current price of $479.00. The base case fair value of $203.88 implies 57.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.